
    
      The combination of gemcitabine-oxaliplatin is attractive in NSCLC patients as it may improve
      the therapeutic index. We are conducting a phase II study to evaluate the response rate and
      toxicity of the gemcitabine-oxaliplatin combination both given every 4 weeks in patients with
      advanced NSCLC.
    
  